CD44 and familial pancreatic carcinoma: In our study, we found that PPARγ might diminish the PDAC stemness via decreasing the expression level of CD44 and CD133 in pancreatic cancer cells, enhancing the killing effect of Gemcitabine on pancreatic cancer cells.